ArticleCancer immunology, immunotherapy : CII2022

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

V Moreno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.